Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
Drug Transporter (DT) Information
| General Information of DT | |||||
|---|---|---|---|---|---|
| DT ID | DTD0500 | ||||
| Gene Name | SLCO2A1 | ||||
| Protein Name | Organic anion transporting polypeptide 2A1 | ||||
| Gene ID | |||||
| UniProt ID | |||||
| TCDB ID | |||||
| 3D Structure |
|
||||
| Synonyms | MATR1; OATP2A1; PGT; PHOAR2; Prostaglandin transporter; SLC21A2; SLCO2A1; Solute carrier family 21 member 2; Solute carrier organic anion transporter family member 2A1 | ||||
| DT Family | Organo Anion Transporter (OAT) Family ; | ||||
| Tissue Specificity | Ubiquitous. Significant expression observed inling, kidney, spleen, and heart. | ||||
| Function | This transporter may mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, as well as PGE1, PGE2 and PGF2A. | ||||
| Disease(s) | Medical abortion [ICD-11: JA00.1] | ||||
| Open angle glaucoma [ICD-11: 9C61] | |||||
| Pulmonary arterial hypertension [ICD-11: BB01.0] | |||||
| Endogenous Substrate(s) | Organoanions | ||||
| Variability Data of This Drug Transporter (DT) | |||||
|
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
|
(α) Microbiota Influence of This DT |
|||||
|
(β) Post-translational Modification of This DT |
|||||
|
(γ) Transcriptional Regulation of This DT |
|||||
|
(δ) Epigenetic Regulation of This DT |
|||||
|
(ε) Exogenous Modulation of This DT |
|||||
|
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
|
(β) Inter-species Structural Differences |
|||||
|
General Variability Data of This DT (VARIDT 1.0) |
|||||
|
(α) Genetic Polymorphisms of This DT |
|||||
|
(β) Disease-specific Protein Abundances of This DT |
|||||
|
(γ) Species- and Tissue-specific DT Abundances |
|||||
| Molecular Transporting Profile of This DT | |||||
|
Full List of Drug(s) Transported by This DT |
|||||
|
Approved Drug |
Click to Show/Hide the Full List of Drug: 4 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
Alprostadil
|
Approved | Drug Info | Erectile dysfunction | HA01 | [1] |
|
Dinoprostone
|
Approved | Drug Info | Medical abortion | JA00.1 | [2] |
|
Iloprost
|
Approved | Drug Info | Pulmonary arterial hypertension | BB01.0 | [1] |
|
Latanoprost
|
Approved | Drug Info | Open angle glaucoma | 9C61 | [3] |
|
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 1 Drugs in Total | ||||
| Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
|
Prostaglandin f2Alpha
|
Preclinical | Drug Info | Solid tumours | 2D4Z | [1] |
|
Endogenous Metabolites (EMs) Handled by This DT |
|||||
|
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 2 EMs in Total | ||||
| EM Name | PubChem CID | Detail | Experimental Material | Ref | |
| Prostaglandin E2 | EM Info | Identified using thiazide-induced hyponatremia patients SLCO2A1 396 Ala/Thr/Glu variants | [4] | ||
| Tetranor-prostaglandin EM | EM Info | Identified using thiazide-induced hyponatremia patients SLCO2A1 396 Ala/Thr/Glu variants | [4] | ||
| References | |||||
| 1 | Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. | ||||
| 2 | Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 2000 Jun 24;273(1):251-60. | ||||
| 3 | The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. | ||||
| 4 | Phenotypic and pharmacogenetic evaluation of patients with thiazide-induced hyponatremia. J Clin Invest. 2017 Sep 1;127(9):3367-3374. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.